Table 1.
Baseline characteristics of study population in the CREDIT registry
| Total cohort | Without comorbidity | With comorbidity | ||||
|---|---|---|---|---|---|---|
| Any | CVD | Fracture | Malignancy | |||
| N (%) | 13,210 (100) | 12,651 (95.8) | 559 (4.2) | 293 (2.2) | 222 (1.7) | 78 (0.6) |
| Demographic features | ||||||
| Female, % | 80.6 | 80.8 | 77.6 | 68.6 | 88.3 | 80.8 |
| Age, ya | 52.9 ± 13.1 | 52.4 ± 13.0 | 62.9 ± 10.8 | 65.6 ± 9.5 | 61.0 ± 11.8 | 60.9 ± 10.4 |
| Age ≥ 60, % | 32.7 | 31.2 | 66.9 | 75.4 | 61.7 | 59.0 |
| Clinical characteristics | ||||||
| RA duration, yb | 4.0 (1.3–10.0) | 4.0 (1.2–10.0) | 6.3 (2.0–13.1) | 6.0 (1.4–12.9) | 7.7 (3.0–15.7) | 4.0 (1.2–10.7) |
| RF/CCP+, % | 83.6 | 83.4 | 86.9 | 86.0 | 86.5 | 89.7 |
| ESR, mm/hb | 34.0 (17.0–60.0) | 33.0 (17.0–60.0) | 41.0 (21.0–66.0) | 40.0 (20.5–67.5) | 39.5 (20.8–66.0) | 45.0 (22.8–65.0) |
| CRP, mg/Lb | 10.3(3.2–30.0) | 10.2 (3.2–30.0) | 11.5 (3.2–35.8) | 12.0 (3.3–39.2) | 9.9 (3.2–35.5) | 7.7 (2.8–29.7) |
| DAS28-CRPa | 4.5 ± 1.7 | 4.4 ± 1.7 | 4.7 ± 1.7 | 4.7 ± 1.7 | 4.7 ± 1.8 | 4.6 ± 1.8 |
| Medications | ||||||
| GC ever, % | 40.6 | 40.5 | 43.1 | 46.1 | 41.9 | 34.6 |
| MTX ever, % | 55.9 | 56.4 | 44.7 | 42.3 | 47.7 | 37.2 |
| bDMARDs, % | 8.3 | 8.2 | 9.3 | 8.9 | 14.4 | 1.3 |
CVD cardiovascular disease, RA rheumatoid arthritis, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GC glucocorticoid, MTX methotrexate, bDMARDs biological disease-modifying antirheumatic drugs
aData are presented as mean ± SD (standard deviation)
bData are presented as median (IQR, interquartile range)